T. Rowe Price Investment Management, Inc.

Position in KYMR — Kymera Therapeutics, Inc.

CIK 1897612 BALTIMORE, MD

Position in KYMR

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$717,520,118

+$262,340,518 QoQ

Shares Held

6,257,261

+14.5% QoQ

Ownership

7.53%

of shares outstanding

% of Portfolio

0.47%

of 13F equity value

Holder Rank

of 273 holders

Holding Since

Sep 2022

11 quarters on record

Voting authority Sole 96% Shared 0% None 4%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. KYMR ranks #4 (5.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc. This page	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$717,520,118	6,257,261	+14.5%	Shares	Sole	2026-08-14
2026-03-31	$455,179,600	5,464,997	+5543.7%	Shares	Sole	2026-05-15
2025-12-31	$7,534,575	96,833	-84.2%	Shares	Sole	2026-02-17
2025-09-30	$34,595,108	611,221	+574.4%	Shares	Sole	2025-11-14
2025-06-30	$3,955,005	90,628	-93.0%	Shares	Sole	2025-08-14
2023-12-31	$32,994,708	1,295,943	-19.5%	Shares	Sole	2024-02-14
2023-09-30	$22,385,894	1,610,496	0.0%	Shares	Sole	2023-11-14
2023-06-30	$37,025,303	1,610,496	-18.2%	Shares	Sole	2023-08-14
2023-03-31	$58,317,025	1,968,175	+0.6%	Shares	Sole	2023-05-15
2022-12-31	$48,821,185	1,955,977	-2.0%	Shares	Sole	2023-02-14
2022-09-30	$43,464,436	1,996,529	—	Shares	Sole	2022-11-14
No filing history on record for this holder in this stock.